Related Experiment Video
Updated: May 5, 2026
23:53
Ole Isacson: Development of New Therapies for Parkinson's Disease
Published on: April 29, 2007
7.5K
[Overcoming neurological diseases-breakthrough for new era]
1Department of Neurology and Neurological Science, Graduate School of Medical and Dental Sciences, Center for Brain Integration Research, Tokyo Medical and Dental University.
Rinsho Shinkeigaku = Clinical Neurology
|December 3, 2013
Summary
Neurological disease treatment is advancing, moving beyond symptom management to disease modification for conditions like Alzheimer's. This progress offers hope for overcoming previously intractable neurological disorders.
Area of Science:
- Neurology
- Neuroscience
- Disease Pathogenesis
Context:
- Historically, neurological diseases were considered intractable.
- Recent research into etiologies and pathogeneses has enabled disease-modifying treatments.
- Conditions like bulbo-spinal muscular atrophy and Alzheimer's disease are now treatable beyond symptomatic relief.
Purpose:
- To highlight progress in treating neurological diseases.
- To share experiences and convey key messages to young neurologists.
- To inspire innovation and collaboration in neurological research and practice.
Summary:
- Advances in understanding neurological disease mechanisms allow for disease modification, not just symptomatic treatment.
- Personal experiences with distal myopathy, amyotrophic lateral sclerosis, and spinocerebellar ataxia illustrate key principles for neurologists.
- The Japanese Society of Neurology aims to improve neurological care through practice, education, and research.
Impact:
- Represents a potential new era in treating neurological disorders.
- Encourages young neurologists to be innovative, collaborative, and globally connected.
- Aims to contribute to the happiness of people worldwide through advancements in neurology.
Related Concept Videos
01:24Parkinson's Disease: Treatment
1.4K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.4K
01:22Alzheimer's Disease: Treatment
1.3K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K
01:24Parkinson Disease l: Introduction
28
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of...
28
01:15Parkinson's Disease: Overview
2.2K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.2K
01:19Multiple Sclerosis l: Introduction
31
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
31
01:35Long-term Potentiation
51.6K
Long-term potentiation, or LTP, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTP is the process of synaptic strengthening that occurs over time between pre- and postsynaptic neuronal connections. The synaptic strengthening of LTP works in opposition to the synaptic weakening of long-term depression (LTD) and together are the main mechanisms that underlie learning and memory.
51.6K